Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.

Buckley HL, Collinson FJ, Ainsworth G, Poad H, Flanagan L, Katona E, Howard HC, Murden G, Banks RE, Brown J, Velikova G, Waddell T, Fife K, Nathan PD, Larkin J, Powles T, Brown SR, Vasudev NS.

BMC Cancer. 2019 Nov 14;19(1):1102. doi: 10.1186/s12885-019-6273-1.

2.

Young Women and Oral Human Papillomavirus-Vaccination Is Associated With Protection.

Katzenellenbogen RA, Fife KH.

JAMA Netw Open. 2019 Oct 2;2(10):e1914038. doi: 10.1001/jamanetworkopen.2019.14038. No abstract available.

PMID:
31651962
3.

Augmenting the randomized controlled trial with real-world data to aid clinical decision making in metastatic renal cell carcinoma: a systematic review and meta-analysis.

Moran M, Nickens D, Adcock K, Bennetts M, Charnley N, Fife K.

Future Oncol. 2019 Dec;15(34):3987-4001. doi: 10.2217/fon-2019-0421. Epub 2019 Oct 18.

4.

The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort.

Klatte T, Gallagher KM, Afferi L, Volpe A, Kroeger N, Ribback S, McNeill A, Riddick ACP, Armitage JN, 'Aho TF, Eisen T, Fife K, Bex A, Pantuck AJ, Stewart GD.

BMC Med. 2019 Oct 3;17(1):182. doi: 10.1186/s12916-019-1419-1.

5.

A Decision Analysis Evaluating Screening for Kidney Cancer Using Focused Renal Ultrasound.

Rossi SH, Klatte T, Usher-Smith JA, Fife K, Welsh SJ, Dabestani S, Bex A, Nicol D, Nathan P, Stewart GD, Wilson ECF.

Eur Urol Focus. 2019 Sep 14. pii: S2405-4569(19)30277-9. doi: 10.1016/j.euf.2019.09.002. [Epub ahead of print]

PMID:
31530498
6.

Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data.

Moran M, Nickens D, Adcock K, Bennetts M, Desscan A, Charnley N, Fife K.

Target Oncol. 2019 Aug;14(4):405-416. doi: 10.1007/s11523-019-00653-5. Review.

7.

Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy.

Hall PE, Shepherd STC, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E, Bahl A, Fife K, Webb A, Crabb SJ, Geldart T, Hill R, Dunlop J, McLaren D, Ackerman C, Wimalasingham A, Beltran L, Nathan P, Powles T.

Eur Urol Focus. 2019 Feb 6. pii: S2405-4569(19)30010-0. doi: 10.1016/j.euf.2019.01.010. [Epub ahead of print]

PMID:
30738795
8.

Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study.

Hansson J, Bartley K, Karagiannis T, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Yim YM, Dimier N, Fittipaldo A, Basset-Séguin N, Hauschild A.

Eur J Dermatol. 2018 Dec 1;28(6):775-783. doi: 10.1684/ejd.2018.3448.

PMID:
30698147
9.

Evaluation of the Performance of the Cobas CT/NG Test for Use on the Cobas 6800/8800 Systems for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Male and Female Urogenital Samples.

Van Der Pol B, Fife K, Taylor SN, Nye MB, Chavoustie SE, Eisenberg DL, Crane L, Hirsch G, Arcenas R, Marlowe EM.

J Clin Microbiol. 2019 Mar 28;57(4). pii: e01996-18. doi: 10.1128/JCM.01996-18. Print 2019 Apr.

10.

Dose escalation of axitinib on disease progression as a strategy in the treatment of metastatic renal cell carcinoma.

Doherty GJ, Lynskey D, Matakidou A, Fife K, Eisen T.

ESMO Open. 2018 Nov 5;3(7):e000445. doi: 10.1136/esmoopen-2018-000445. eCollection 2018.

11.

Treatable causes of diarrhoea in patients on tyrosine kinase inhibitors for metastatic renal cell carcinoma.

Lightowlers SV, Greef B, Eisen T, Matakidou A, Fife K, Cameron EA.

Ann Oncol. 2019 Jan 1;30(1):150-151. doi: 10.1093/annonc/mdy469. No abstract available.

PMID:
30358823
12.

External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Marconi L, de Bruijn R, van Werkhoven E, Beisland C, Fife K, Heidenreich A, Kapoor A, Karam J, Kauffmann C, Klatte T, Ljungberg B, Matin S, Sjoberg D, Staehler M, Stewart GD, Tanguay S, Uzzo R, Welsh S, Wood L, Wood C, Bex A.

World J Urol. 2018 Dec;36(12):1973-1980. doi: 10.1007/s00345-018-2427-z. Epub 2018 Aug 1.

PMID:
30069581
13.

Herpes Therapy Enters the Molecular Age.

Fife KH.

J Infect Dis. 2018 Oct 20;218(11):1689-1690. doi: 10.1093/infdis/jiy374. No abstract available.

PMID:
30020482
14.

Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial.

Van Wagoner N, Fife K, Leone PA, Bernstein DI, Warren T, Panther L, Novak RM, Beigi R, Kriesel J, Tyring S, Koltun W, Lucksinger G, Morris A, Zhang B, McNeil LK, Tasker S, Hetherington S, Wald A.

J Infect Dis. 2018 Nov 5;218(12):1890-1899. doi: 10.1093/infdis/jiy415.

PMID:
29982727
15.

Behavior and health beliefs as predictors of HIV testing among women: a prospective study of observed HIV testing.

Fan H, Fife KH, Cox D, Cox AD, Zimet GD.

AIDS Care. 2018 Aug;30(8):1062-1069. doi: 10.1080/09540121.2018.1442555. Epub 2018 Feb 22.

16.

Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.

Klatte T, Fife K, Welsh SJ, Sachdeva M, Armitage JN, 'Aho T, Riddick AC, Matakidou A, Eisen T, Stewart GD.

World J Urol. 2018 Mar;36(3):417-425. doi: 10.1007/s00345-017-2154-x. Epub 2017 Dec 18.

PMID:
29256020
17.

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.

Basset-Séguin N, Hauschild A, Kunstfeld R, Grob J, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Arenberger P, Fife K, Raimundo A, Dika E, Dimier N, Fittipaldo A, Xynos I, Hansson J.

Eur J Cancer. 2017 Nov;86:334-348. doi: 10.1016/j.ejca.2017.08.022. Epub 2017 Nov 5.

18.

Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases.

Wong KY, Fife K, Lear JT, Price RD, Durrani AJ.

Plast Reconstr Surg Glob Open. 2017 Jul 21;5(7):e1424. doi: 10.1097/GOX.0000000000001424. eCollection 2017 Jul.

19.

Treatment of succinate dehydrogenase B-associated renal cancer.

Fife K, Warren A.

BMJ Case Rep. 2017 Aug 7;2017. pii: bcr-2017-219626. doi: 10.1136/bcr-2017-219626.

20.

Causal role for the subthalamic nucleus in interrupting behavior.

Fife KH, Gutierrez-Reed NA, Zell V, Bailly J, Lewis CM, Aron AR, Hnasko TS.

Elife. 2017 Jul 25;6. pii: e27689. doi: 10.7554/eLife.27689.

21.

The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion.

Donnell D, Ramos E, Celum C, Baeten J, Dragavon J, Tappero J, Lingappa JR, Ronald A, Fife K, Coombs RW; Partners PrEP Study Team.

AIDS. 2017 Sep 10;31(14):2007-2016. doi: 10.1097/QAD.0000000000001577.

22.

Clinical Validation of a Test for the Diagnosis of Vaginitis.

Gaydos CA, Beqaj S, Schwebke JR, Lebed J, Smith B, Davis TE, Fife KH, Nyirjesy P, Spurrell T, Furgerson D, Coleman J, Paradis S, Cooper CK.

Obstet Gynecol. 2017 Jul;130(1):181-189. doi: 10.1097/AOG.0000000000002090.

23.

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.

Colomba E, Le Teuff G, Eisen T, Stewart GD, Fife K, Larkin J, Biondo A, Pickering L, Srinivasan A, Boyle H, Derosa L, Sternberg CN, Recine F, Ralph C, Saldana C, Barthélémy P, Bernhard JC, Gurney H, Verhoest G, Vauleon E, Bigot P, Berger J, Pfister C, Gravis G, Rodier JM, Culine S, Caty A, Rolland F, Priou F, Escudier B, Albiges L.

Eur J Cancer. 2017 Jul;80:55-62. doi: 10.1016/j.ejca.2017.03.011. Epub 2017 May 23.

PMID:
28549248
24.

Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial.

Bernstein DI, Wald A, Warren T, Fife K, Tyring S, Lee P, Van Wagoner N, Magaret A, Flechtner JB, Tasker S, Chan J, Morris A, Hetherington S.

J Infect Dis. 2017 Mar 15;215(6):856-864. doi: 10.1093/infdis/jix004.

25.

Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).

Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, Ngai Y, Muthukumar D, Thompson J, Harden S, Middleton G, Fife KM, Crosse B, Taylor P, Nash S, Hackshaw A.

J Clin Oncol. 2017 May 10;35(14):1506-1514. doi: 10.1200/JCO.2016.69.7391. Epub 2017 Feb 27.

26.

Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.

Wald A, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Fife K, Selke S, Huang ML, Stobernack HP, Zimmermann H, Corey L, Birkmann A, Ruebsamen-Schaeff H.

JAMA. 2016 Dec 20;316(23):2495-2503. doi: 10.1001/jama.2016.18189. Erratum in: JAMA. 2017 Feb 14;317(6):648.

PMID:
27997653
27.

Ventral tegmental area glutamate neurons co-release GABA and promote positive reinforcement.

Yoo JH, Zell V, Gutierrez-Reed N, Wu J, Ressler R, Shenasa MA, Johnson AB, Fife KH, Faget L, Hnasko TS.

Nat Commun. 2016 Dec 15;7:13697. doi: 10.1038/ncomms13697.

28.

Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma.

Fife K, Herd R, Lalondrelle S, Plummer R, Strong A, Jones S, Lear JT.

Future Oncol. 2017 Jan;13(2):175-184. Epub 2016 Sep 19. Review.

PMID:
27640448
29.

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.

Lacouture ME, Dréno B, Ascierto PA, Dummer R, Basset-Seguin N, Fife K, Ernst S, Licitra L, Neves RI, Peris K, Puig S, Sokolof J, Sekulic A, Hauschild A, Kunstfeld R.

Oncologist. 2016 Oct;21(10):1218-1229. Epub 2016 Aug 10. Review.

30.

Human Papillomavirus DNA Detection in Older Women-Implications for Cancer Screening and Prevention.

Ermel AC, Fife KH.

J Infect Dis. 2016 Sep 1;214(5):657-8. doi: 10.1093/infdis/jiw075. Epub 2016 Mar 23. No abstract available.

31.

A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK).

Powles T, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E, Bhal A, Fife K, Webb A, Crabb S, Geldart T, Hill R, Dunlop J, Hall PE, McLaren D, Ackerman C, Beltran L, Nathan P.

Ann Oncol. 2016 May;27(5):880-6. doi: 10.1093/annonc/mdw014. Epub 2016 Jan 22.

32.

Transient Increase in Herpes Simplex Virus Type 2 (HSV-2)-Associated Genital Ulcers Following Initiation of Antiretroviral Therapy in HIV/HSV-2-Coinfected Individuals.

Fife KH, Mugwanya K, Thomas KK, Baeten JM, Celum C, Bukusi E, de Bruyn G, Mujugira A, Vwalika B, Wald A, Lingappa JR; Partners in Prevention HSV/HIV Transmission Study Team.

J Infect Dis. 2016 May 15;213(10):1573-8. doi: 10.1093/infdis/jiv765. Epub 2015 Dec 23.

33.

Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples.

Magaret AS, Mujugira A, Hughes JP, Lingappa J, Bukusi EA, DeBruyn G, Delany-Moretlwe S, Fife KH, Gray GE, Kapiga S, Karita E, Mugo NR, Rees H, Ronald A, Vwalika B, Were E, Celum C, Wald A; Partners in Prevention HSV/HIV Transmission Study Team.

Clin Infect Dis. 2016 Feb 15;62(4):456-61. doi: 10.1093/cid/civ908. Epub 2015 Nov 17.

34.

Evolving treatment options for melanoma brain metastases.

Ajithkumar T, Parkinson C, Fife K, Corrie P, Jefferies S.

Lancet Oncol. 2015 Oct;16(13):e486-97. doi: 10.1016/S1470-2045(15)00141-2. Review.

PMID:
26433822
35.

Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.

Gerety EL, Lawrence EM, Wason J, Yan H, Hilborne S, Buscombe J, Cheow HK, Shaw AS, Bird N, Fife K, Heard S, Lomas DJ, Matakidou A, Soloviev D, Eisen T, Gallagher FA.

Ann Oncol. 2015 Oct;26(10):2113-8. doi: 10.1093/annonc/mdv289. Epub 2015 Jul 22.

36.

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.

Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Jouary T, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Williams S, Fittipaldo A, Xynos I, Hansson J.

Lancet Oncol. 2015 Jun;16(6):729-36. doi: 10.1016/S1470-2045(15)70198-1. Epub 2015 May 13.

PMID:
25981813
37.

Frequency of false positive rapid HIV serologic tests in African men and women receiving PrEP for HIV prevention: implications for programmatic roll-out of biomedical interventions.

Ndase P, Celum C, Kidoguchi L, Ronald A, Fife KH, Bukusi E, Donnell D, Baeten JM; Partners PrEP Study Team.

PLoS One. 2015 Apr 17;10(4):e0123005. doi: 10.1371/journal.pone.0123005. eCollection 2015.

38.

Pazopanib for the treatment of renal cell carcinoma.

Welsh SJ, Fife K.

Future Oncol. 2015;11(8):1169-79. doi: 10.2217/fon.14.274. Review.

PMID:
25832874
39.

Solitary lesion on the ear.

Atkar RK, Meligonis G, Godic A, Fife K, Burrows NP.

Clin Exp Dermatol. 2015 Jul;40(5):583-5. doi: 10.1111/ced.12603. Epub 2015 Feb 10. No abstract available.

PMID:
25677962
40.

Host genetic and viral determinants of HIV-1 RNA set point among HIV-1 seroconverters from sub-saharan Africa.

Mackelprang RD, Carrington M, Thomas KK, Hughes JP, Baeten JM, Wald A, Farquhar C, Fife K, Campbell MS, Kapiga S, Gao X, Mullins JI, Lingappa JR.

J Virol. 2015 Feb;89(4):2104-11. doi: 10.1128/JVI.01573-14. Epub 2014 Dec 3.

41.

The effects of HIV testing advocacy messages on test acceptance: a randomized clinical trial.

Kasting ML, Cox AD, Cox D, Fife KH, Katz BP, Zimet GD.

BMC Med. 2014 Nov 6;12:204. doi: 10.1186/s12916-014-0204-4.

42.

Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.

Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Coombs RW, Hendrix C, Marzinke MA, Frenkel L, Haberer JE, Bangsberg D, Celum C; Partners PrEP Study Team.

Lancet Infect Dis. 2014 Nov;14(11):1055-1064. doi: 10.1016/S1473-3099(14)70937-5. Epub 2014 Oct 7.

43.

Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective.

Lear JT, Corner C, Dziewulski P, Fife K, Ross GL, Varma S, Harwood CA.

Br J Cancer. 2014 Oct 14;111(8):1476-81. doi: 10.1038/bjc.2014.270. Epub 2014 Sep 11.

44.

Management of melanoma.

Corrie P, Hategan M, Fife K, Parkinson C.

Br Med Bull. 2014 Sep;111(1):149-62. doi: 10.1093/bmb/ldu019. Review.

PMID:
25190764
45.

Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.

Celum C, Morrow RA, Donnell D, Hong T, Hendrix CW, Thomas KK, Fife KH, Nakku-Joloba E, Mujugira A, Baeten JM; Partners PrEP Study Team.

Ann Intern Med. 2014 Jul 1;161(1):11-9. doi: 10.7326/M13-2471. Erratum in: Ann Intern Med. 2016 Dec 6;165(11):832.

PMID:
24979446
46.

Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial.

Spathis A, Fife K, Blackhall F, Dutton S, Bahadori R, Wharton R, O'Brien M, Stone P, Benepal T, Bates N, Wee B.

J Clin Oncol. 2014 Jun 20;32(18):1882-8. doi: 10.1200/JCO.2013.54.4346. Epub 2014 Apr 28.

PMID:
24778393
47.

British HIV Association guidelines for HIV-associated malignancies 2014.

Bower M, Palfreeman A, Alfa-Wali M, Bunker C, Burns F, Churchill D, Collins S, Cwynarski K, Edwards S, Fields P, Fife K, Gallop-Evans E, Kassam S, Kulasegaram R, Lacey C, Marcus R, Montoto S, Nelson M, Newsom-Davis T, Orkin C, Shaw K, Tenant-Flowers M, Webb A, Westwell S, Williams M; British HIV Association.

HIV Med. 2014 Mar;15 Suppl 2:1-92. doi: 10.1111/hiv.12136. No abstract available.

48.

Unreported antiretroviral use by HIV-1-infected participants enrolling in a prospective research study.

Kahle EM, Kashuba A, Baeten JM, Fife KH, Celum C, Mujugira A, Essex M, De Bruyn G, Wald A, Donnell D, John-Stewart G, Delany-Moretlwe S, Mugo NR, Farquhar C, Lingappa JR; Partners in Prevention HSVHIV Transmission Study Team.

J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):e90-4. doi: 10.1097/QAI.0b013e3182a2db02. No abstract available.

49.

Helicase-primase inhibitor pritelivir for HSV-2 infection.

Wald A, Corey L, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Kriesel J, Fife K, Galitz L, Stoelben S, Huang ML, Selke S, Stobernack HP, Ruebsamen-Schaeff H, Birkmann A.

N Engl J Med. 2014 Jan 16;370(3):201-10. doi: 10.1056/NEJMoa1301150.

50.

HIV-1 subtype C is not associated with higher risk of heterosexual HIV-1 transmission: a multinational study among HIV-1 serodiscordant couples.

Kahle E, Campbell M, Lingappa J, Donnell D, Celum C, Ondondo R, Mujugira A, Fife K, Mugo N, Kapiga S, Mullins JI, Baeten JM; Partners in Prevention HSVHIV Transmission Study Team.

AIDS. 2014 Jan 14;28(2):235-43. doi: 10.1097/QAD.0000000000000024.

Supplemental Content

Support Center